EP3432860A1 - Hydrolyzed collagen compositions and methods of making thereof - Google Patents

Hydrolyzed collagen compositions and methods of making thereof

Info

Publication number
EP3432860A1
EP3432860A1 EP17770897.1A EP17770897A EP3432860A1 EP 3432860 A1 EP3432860 A1 EP 3432860A1 EP 17770897 A EP17770897 A EP 17770897A EP 3432860 A1 EP3432860 A1 EP 3432860A1
Authority
EP
European Patent Office
Prior art keywords
acid
hydrolyzed collagen
chicken sternum
chicken
mole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17770897.1A
Other languages
German (de)
French (fr)
Other versions
EP3432860B1 (en
EP3432860A4 (en
Inventor
Ali ELNAJJAR
Ali MOURAD
Mark Ernst Brandt
Christopher Lippelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avicenna Nutraceutical LLC
Original Assignee
Avicenna Nutraceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avicenna Nutraceutical LLC filed Critical Avicenna Nutraceutical LLC
Publication of EP3432860A1 publication Critical patent/EP3432860A1/en
Publication of EP3432860A4 publication Critical patent/EP3432860A4/en
Application granted granted Critical
Publication of EP3432860B1 publication Critical patent/EP3432860B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08HDERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00Macromolecular products derived from proteins
    • C08H1/06Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281Proteins, e.g. gelatin or collagen
    • A23L29/284Gelatin; Collagen
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin

Abstract

Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.

Description

HYDROLYZED COLLAGEN COMPOSITIONS AND METHODS OF
MAKING THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority upon U.S. provisional application Serial No. 62/311,575 filed March 22, 2016. This application is hereby incorporated by reference in its entirety for all of its teachings.
BACKGROUND
Collagen preparations have been used in a variety of capacities, from gelling agents in food, to pharmaceuticals and health aids, to photography, cosmetic manufacturing, and adhesives. Within the health industry, collagen preparations have been used to enhance athletic performance by supplying essential amino acids and shortening recovery time after exercise, and have also been used as weight loss aids and digestive aids as well as to relieve pain, reduce inflammation, and improve joint function for patients with osteoarthritis and rheumatoid arthritis. Collagen preparations have been used as supplements to combat osteoporosis and improve the condition of fingernails and hair. In the cosmetic industry, meanwhile, collagen preparations are available as topical products for use on the skin to increase skin suppleness, reduce the appearance of wrinkles and fine lines, and to reduce the appearance of stretch marks.
Although the raw materials for extracting collagen are readily available as byproducts from other industries, such as the fishing and poultry processing industries, current methods for producing collagen are expensive and time- consuming. Cartilage tissue must be separated from meat and bones and chopped. Hydrolysis of collagen often requires the sequential use of multiple enzymes, each of which likely performs best in a different set of reaction conditions (e.g., temperature, salt content, solution pH, etc.). Further, specialized digestive enzymes are expensive and the cost increases when multi-enzyme cocktails are used, especially on an industrial scale. Following hydrolysis, a number of purification steps are often required, including the use of decolorizing agents, antibacterial and antifungal agents, and the like. Product odor is also a consideration; collagen preparations with strong odors will be unsuitable especially for incorporation into cosmetic or food products.
It would thus be advantageous to have an enzyme- free process for producing hydrolyzed collagen preparations. It would further be advantageous if this process resulted in a product or products with a white or light yellow color and minimal to no odor. Still further, it would be advantageous if collagen preparations produced according to this process were able to supply essential minerals in addition to the amino acids and peptides naturally present in the preparations. The present invention addresses these needs.
SUMMARY
Disclosed herein are hydrolyzed collagen compositions. The compositions are inexpensive to make and can be produced without the use of proteolytic enzymes, decolorizing agents, antibacterial and antifungal agents, and the like. Further, the compositions are substantially free of odors and are white to light yellow in color and are suitable to be used as dietary supplements. Also disclosed are methods for producing the compositions.
The advantages of the invention will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.
DETAILED DESCRIPTION
Before the present compounds, compositions, and/or methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific compounds, synthetic methods, or uses, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.
In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:
It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an acid" includes mixtures of two or more such acids, and the like.
"Optional" or "optionally" means that the subsequently-described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
As used herein, "cartilage" refers to a type of connective tissue in animals. It is a flexible tissue that is somewhat more rigid than muscle and is found in various locations throughout the body including joints, the rib cage, the nose and ear, bronchial tubes, trachea, between the vertebra, and so forth. Cartilage tissue contains a large amount of extracellular matrix that is high in collagen and other proteoglycans. Chondrocytes are matrix-producing cells that have become trapped in the matrix.
"Collagen" is a structural protein found in connective tissue; it frequently takes the form of fibrils arranged in a triple helix. Fibrillar types of collagen include Types I, II, III, V, and XI. Type I collagen makes up a great deal of the organic part of bone as well as being found in skin, tendons, blood vessels, and organs, while type III collagen is commonly found near or with type I. On the other hand, cartilage is composed primarily of type II collagen. Other types of cartilage are less common and may be found in membranes, on cell surfaces, and associated with hair and placental structures.
As used herein, "hydrolysis" refers to the breaking of a chemical bond in a molecule via the molecule's reaction with water. Thus, a nucleic acid would be hydrolyzed into oligonucleotides and component nucleotides, a protein into peptides and amino acids, a polysaccharide into oligosaccharides and component sugars, and so forth. The degree of completion of hydrolysis is dependent upon reaction conditions. Hydrolysis can be accomplished in basic solution, in acidic solution, in a salt solution (usually when the salt is a weak acid or base), or using an enzyme.
"Hydrolyzed collagen" as used herein is collagen that has been subjected to a hydrolysis process. "Gelatin" is collagen that has been partially hydrolyzed and possesses specific properties such as solubility in hot water and a similar amino acid composition to the parent collagen.
The sternum, or breastbone, is a large bone to which the pectoral muscles are attached. In avians such as chickens, the sternum is positioned under the body and is enlarged in size for attachment of powerful flight muscles. Avian sterna are typically associated with a large proportion of cartilage that is rich in type II collagen.
As used herein, "neutralization" refers to the treatment of an acidic reaction solution with an approximately quantitative amount of a base. Neutralization with base can stop an acidic hydrolysis reaction, for example.
An "anti-bacterial agent" is any compound or composition or treatment that destroys bacteria. Alternatively, an anti-bacterial agent can suppress the growth of bacteria or can prevent bacteria from reproducing. Ultraviolet light, heat treatment, certain chemicals such as bleach or ethanol, and antibiotics are considered anti- bacterial.
As used herein, the term "about" is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above" or "a little below" the endpoint without affecting the desired result.
Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of "about 1 to about 5" should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also to include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3, and 4 and sub-ranges such as from 1-3, from 2-4, and from 3-5, etc., as well as 1, 2, 3, 4, and 5, individually. This same principle applies to ranges reciting only one numerical value as a minimum or a maximum. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described.
As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience.
However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the list solely based on their presentation in a common group without indications to the contrary.
Disclosed are materials and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed compositions and methods. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc., of these materials are disclosed, that while specific reference of each various individual and collective combination and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if an acid is disclosed and a number of different neutralizing bases are discussed, each and every combination and permutation of acid and base that is possible is specifically contemplated unless specifically indicated to the contrary. For example, if a class of molecules A, B, and C are disclosed, as well as a class of molecules D, E, and F, and an example of a combination A + D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, in this example, each of the combinations A + E, A + F, B + D, B + E, B + F, C + D, C + E, and C + F, are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination of A + D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A + E, B + F, and C + E is specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination of A + D. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there exist a variety of additional steps that can be performed with any specific embodiment or combination of embodiments of the disclosed methods, each such combination is specifically contemplated and should be considered disclosed.
References in the specification and concluding claims to parts by weight of a particular element or component denote the weight relationship between the element or component and any other elements or components in the compound or composition for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight of component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
A weight percent of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
Provided herein are compositions containing collagen as well as methods to produce the compositions. In one aspect, the collagen is hydrolyzed. In another aspect, the collagen is sourced from vertebrate cartilage. In a further aspect, the vertebrate is a fish, mammal, or avian. In a still further aspect, the vertebrate is a chicken and the cartilage is sternal cartilage, while the collagen is type II collagen.
In one aspect, provided herein is a method for producing hydrolyzed collagen, the method including the following steps: (a) heating a chicken sternum in the presence of an aqueous acid at an elevated temperature for a time period to produce a first composition;
(b) filtering the first composition to remove the supernatant;
(c) neutralizing the acid present in the supernatant to produce a neutralized supernatant; and
(d) removing the water in the neutralized supernatant to produce the hydrolyzed collagen.
Each step of the process described herein is discussed in detail below.
In one aspect, prior to step (a), the chicken sternum is removed from the chicken skeleton. Here, all of the meat is removed from the chicken sternum or substantially all of the meat is removed (e.g., greater than 90%, greater than 95%, or greater than 99%).
In another aspect, the chicken sternum is treated with an anti-bacterial agent prior to step (a). Examples of anti-bacterial agents useful herein include, but are not limited to, ethanol, isopropanol, chlorine, bleach, a peroxide, a quaternary ammonium compound, or a combination thereof. In a further aspect, prior to step (a), the chicken sternum is boiled then the temperature is reduced prior to hydrolysis. In an alternative aspect, if the chicken sternum is processed immediately, an anti-bacterial agent is not required.
After the chicken sternum has been removed, it can be processed further prior to hydrolysis. For example, the chicken sternum can be chopped or pulverized to increase the surface area of the sternum.
After the chicken sternum has been removed, it is subjected to acid hydrolysis. The selection of the hydrolysis conditions in step (a) is important with respect to producing highly pure hydrolyzed collagen that has little to no odor or discoloration.
In one aspect, the acid is a strong acid. In a further aspect, the acid is selected from hydrochloric acid, hydroiodic acid, hydrobromic acid, perchloric acid, nitric acid, sulfuric acid, or a combination thereof. In one aspect, the acid is present in solution at a concentration of from 0.5 M to 4 M, or is about 0.5 M, about 1 M, about 1.5 M, about 2 M, about 2.5 M, about 3 M, about 3.5 M, or about 4 M, where any value can be a lower and upper endpoint of a range (e.g., 1 M to 3 M). In another aspect, a lower acid concentration will result in less base needed for neutralization. In some aspects, when the acid concentration was less thanl M, little or no hydrolysis was observed at 12 hours.
The ratio of the amount of acid to the chicken sternum is important with respect to the purity of the final hydrolyzed collagen. In one aspect, the ratio of the chicken sternum per mole of acid is from 500 grams to 5,000 grams of chicken sternum per mole of acid, or is about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 1,000; 1,100; 1,200; 1,300; 1,400; 1,500; 2,000; 2,500; 3,000; 3,500; 4,000; 4,500, or 5,000 grams of chicken sternum per mole of acid, where any value can be a lower and upper endpoint of a range (e.g., 500 to 750). Thus, by varying the amount of the chicken sternum and concentration of the acid, it is possible to vary the ratios above. The Examples provide calculations for determining these ratios.
The hydrolysis step (a) is conducted at an elevated temperature. In one aspect, the elevated temperature is from 50 °C to boiling, or is about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, about 90 °C, about 95 °C, or about 100 °C, where any value can be a lower and upper endpoint of a range (e.g., 55 °C to 65 °C).
The duration of the hydrolysis step (a) is also important with respect to producing highly pure hydrolyzed collagen. In one aspect, the duration of hydrolysis is from 2 hours to 48 hours, or is about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 24 hours, or about 48 hours where any value can be a lower and upper endpoint of a range (e.g., 8 to 12 hours). In another aspect, the duration of hydrolysis is from 10 hours to 20 hours, 15 hours to 20 hours, 16 hours to 18 hours, or about 17 hours.
As discussed above, the conditions of the hydrolysis step are important with respect to producing highly pure hydrolyzed collagen. For example, hydrolysis slows when the reaction temperature drops below 50 °C. Furthermore, longer heating times result in more highly-colored products. In one aspect, the chicken sternum is heated in the presence of hydrochloric acid at a temperature of from 58 °C to 62 °C for a time period of 16 to 18 hours. Further in this aspect, the chicken sternum can be present in a ratio of from 500 grams to 1,000 grams per mole of acid.
In another aspect, the hydrolysis reaction can be performed in open air, under vacuum, or under a nitrogen atmosphere. The hydrolysis step can be performed in a batch process or continuous process.
In one aspect, after hydrolysis step (a), the resulting mixture is optionally filtered to remove any insoluble materials. Standard filtration techniques can be used in this aspect.
After the hydrolysis step (a), a neutralization step is performed. In one aspect, the mixture produced after step (a) can be neutralized directly. In another aspect, if a filtration step is performed, the acid in the supernatant is neutralized with a base. The concentration and amount of base used in the neutralization step is generally in the amount to completely neutralize all of the acid present in the supernatant or substantially neutralize all of the acid (e.g., greater than 90%, greater than 95%, or greater than 99%).
In one aspect, the base is a strong base. In a further aspect, the strong base is sodium hydroxide, potassium hydroxide, calcium hydroxide, or a combination thereof. In an alternative aspect, the base is a weak base. Further in this aspect, the weak base is calcium carbonate, sodium carbonate, potassium carbonate, ammonia, sodium bicarbonate, or a combination thereof. In either of these aspects, the strong or weak base can be an alkali metal base or an alkaline earth metal base. In a further aspect, the acid is neutralized with calcium hydroxide or calcium carbonate. In one aspect, calcium carbonate is preferred for neutralizing the substrate since calcium salts such as calcium chloride are left behind in the hydrolyzed collagen composition and these are safe for oral consumption by humans or other mammals. In a further aspect, the hydrolyzed collagen composition may provide some health benefits such as bone and joint support to a subject who consumes the composition. In a still further aspect, any calcium salts left behind after drying the hydrolyzed collagen composition provide a further health benefit such as bone support to a subject who consumes the composition. In an alternative aspect, drying a hydrolyzed collagen composition that has been neutralized by calcium carbonate requires less time and energy than drying a hydrolyzed collagen composition neutralized with another base, since calcium carbonate adsorbs less water than other bases.
After neutralization, the resulting mixture can be filtered to remove any insoluble materials and isolate the supernatant containing the hydrolyzed collagen. In the alternative, if a filtration step was performed after hydrolysis and prior to neutralization, no additional filtration is required of the neutralized supernatant. The water is removed from the neutralized supernatant to produce a dry solid or powder of the hydrolyzed collagen. Methods for removing the water from the supernatant include, but are not limited to, rotary evaporation, lyophilization, oven drying, or spray drying.
Also disclosed herein are hydrolyzed collagen products produced by the methods described herein. In one aspect, the hydrolyzed collagen has an average molecular weight of less than 10 kDa. In a further aspect, the hydrolyzed collagen has an average molecular weight of 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa, or 10 kDa, or from about 3 kDa to about 5 kDa. In another aspect, the hydrolyzed collagen contains one or more calcium salts (e.g., CaC^) in an amount of less than 25% by weight of the hydrolyzed collagen, or about 5%, about 10%, about 15%, about 20%, or about 25% by weight of the hydrolyzed collagen where any value can be a lower and upper endpoint of a range (e.g., 10% to 25%). In one aspect, the average molecular weight of the hydrolyzed collagen can be altered by changing the hydrolysis reaction time.
In another aspect, the hydrolyzed collagen composition described herein contains hyaluronic acid in an amount of less than 10% by weight of the hydrolyzed collagen, or contains hyaluronic acid at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 9% by weight of the hydrolyzed collagen where any value can be a lower and upper endpoint of a range (e.g., 2% to 9%). In another aspect, the hydrolyzed collagen composition contains less than 2% by weight, less than 1.5% by weight, or less than 1% by weight hyaluronic acid.
In another aspect, the hydrolyzed collagen composition described herein contains chondroitin sulfate in an amount of less than 10% by weight of the hydrolyzed collagen, or contains chondroitin sulfate at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, or about 9% by weight of the hydrolyzed collagen where any value can be a lower and upper endpoint of a range (e.g., 2% to 9%). In this aspect, the presence of chondroitin sulfate is derived from the chicken sternum and not an additional supplement. In another aspect, the hydrolyzed collagen composition contains less than 4% by weight chondroitin sulfate. In a further aspect, hydrolyzed collagen composition contains from 0.5% to 4% by weight chondroitin sulfate.
In a further aspect, the hydrolyzed collagen compositions described herein have little to no odor compared to other hydrolyzed collagen compositions. In another aspect, the hydrolyzed collagen compositions described herein have little or no color compared to other hydrolyzed collagen compositions and appear white or light yellow in color. In one aspect, color and odor are removed with the use of a decolorizing agent such as, for example, activated carbon or activated charcoal. In another aspect, charcoal or a decolorizing agent is not needed to remove color and odor from the hydrolyzed collagen composition.
In one aspect, the total protein level of the hydrolyzed collagen composition is greater than 80%, greater than 85%, or greater than 90%. In another aspect, the total collagen level of the hydrolyzed collagen composition is greater than 60%, greater than 65%, or greater than 70%.
EXAMPLES
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, and methods described and claimed herein are made and evaluated. The examples are intended to be purely exemplary and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric. Numerous variations and combinations of reaction conditions, e.g., component concentrations, desired solvents, solvent mixtures, temperatures, pressures, and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such processes and conditions.
Ratio of Amount of Chicken Sternum per Mole of Acid
In Example 1 , the amount of cartilage treated with the HCl was 5 g per 2 mL of acid. The following calculation was used to determine the amount of chicken sternum per mole of acid.
Moles of HCl in 2 mL of 2 M solution
2 moles HCl v IL
X X 2 mL = 0.004 moles HCl
1 L 1000 mL
Ratio of 5 g chicken sternum treated with 2 mL of 2 M HCl (i.e., 0.004 moles of HCl)
5 g chicken sternum _ 1 ,250 g chicken sternum 0.004 moles HCl m°le HCl
Thus, when 5 g of chicken sternum is treated with 2mL of 2 M HCl, this is equivalent to 1,250 g of chicken sternum treated with 1 mole of aqueous HCl.
Example 1: General Procedure
The following general procedure was used to prepare collagen hydrolysate from chicken sternal cartilage. Some parameters were varied during the course of optimization of conditions (see Example 2).
(1) Sternal cartilage was removed from chicken skeleton. Cartilage was either used immediately or stored in a volume of 70% ethanol sufficient to cover the biological material.
(2) 0.5 mL of 2M aqueous HCl per gram of cartilage was added.
(3) The mixture was placed in a reaction vessel at 60 °C and stirred vigorously for 12 hours.
(4) Optionally, the mixture was filtered. The filter was rinsed with ultrapure water to remove residual soluble material.
(5) The supernatant liquid was neutralized with either 0.25 mL of sodium hydroxide per mL of HCl originally used or, alternatively, with 0.11 g calcium carbonate per mL of HCl originally used. Neutralization with CaCC>3 results in the evolution of carbon dioxide gas.
(6) Water is removed from the neutralized supernatant. Lyophilization and/or spray drying were typically used. The final hydrolyzed collagen product is an off- white material having a "fluffy" appearance (Figs. 1 and 2).
Example 2: Experimental Permutations
Various parameters in the procedure of Example 1 were altered in order to optimize product yield. Results from several example procedures are presented in Table 1. Hydrolysis was evaluated using denaturing (SDS) polyacrylamide gel electrophoresis.
(a) Three replicates performed under similar set of conditions.
(b) Solids from filtering were analyzed.
(c) Two replicates performed under similar set of conditions.
(d) Unfiltered product analyzed.
(e) Filtrate analyzed.
(f) Hydrolysis reaction carried out under vacuum.
(g) Base added to neutralize acid at the completion of hydrolysis reaction.
(h) Appearance of bands in the SDS-PAGE gel that had migrated outside the sample wells was considered positive evidence of hydrolysis. In some cases, hydrolysis may have generated small peptides that ran off the end of the gel or were too small to stain.
Example 3: Characterization of Products
Products were subjected to HPLC analysis, method ALC190A, performed by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA). This method detects and quantifies amino acids in bound form, after protein hydrolysis. Results from an example product are presented in Table 2.
In another experiment, hydrolysis was performed using the protocol in Example 1 with the exception that hydrolysis was conducted at 60 °C for 17 hours using 1 M HCl (ratio of 5 g cartilage per 2 mL of 1 M HCl). The amino acid content of the resulting hydrolysate is provided in Table 3 (two samples).
Table 3: Amino Acid Analysis
Amino Acid % of Composition
Alanine 4.51 7.11
Arginine 4.66 5.35
Aspartic acid 4.52 7.58
Cystine 0.41 0.60
Glutamic acid 8.19 12.36
Glycine 10.46 13.92
Histidine 1.21 1.55
Isoleucine 1.61 2.49
Leucine 3.29 4.18 Lysine 2.55 4.66
Methionine 1.00 1.30
Phenylalanine 1.86 1.90
Proline 6.04 8.51
Serine 2.00 3.30
Threonine 4.41 3.38
Tryptophan 0.29 0.34
Tyrosine 0.64 1.20
Valine 2.46 3.44
Throughout this publication, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the methods, compositions, and compounds herein.
Various modifications and variations can be made to the methods, compositions, and compounds described herein. Other aspects of the methods, compositions, and compounds will be apparent from consideration of the specification and practice of the methods, compositions, and compounds disclosed herein. It is intended that the specification and examples be considered as exemplary.

Claims

claimed:
A method for producing hydrolyzed collagen, the method comprising
(a) heating a chicken sternum in the presence of an aqueous acid at a temperature of from 55 °C to 65 °C for 8 to 20 hours, wherein the ratio of chicken sternum per mole of acid is from 250 g chicken sternum/mole of acid to 2,000 g chicken sternum/mole of acid to produce a first composition;
(b) optionally filtering the first composition to remove the supernatant;
(c) neutralizing the acid present in the supernatant to produce a neutralized supernatant; and
(d) removing the water in the neutralized supernatant to produce the
hydrolyzed collagen.
The method of claim 1 , wherein chicken sternum is removed from the chicken skeleton prior to step (a).
The method of claim 1 , wherein chicken sternum is treated with an antibacterial agent prior to step (a).
The method of claim 1 , wherein the chicken sternum is heated in the presence of an aqueous acid at a temperature of from 58 °C to 62 °C for 16 to 18 hours. The method of claim 1 , wherein the acid comprises hydrochloric acid.
The method of claim 1 , wherein the ratio of chicken sternum per mole of acid is from 500 g chicken sternum/mole of acid to 5,000 g chicken sternum/mole of acid.
The method of claim 1 , wherein the ratio of chicken sternum per mole of acid is from 500 g chicken sternum/mole of acid to 1,000 g chicken sternum/mole of acid.
The method of claim 1 , wherein the supernatant is neutralized with an alkali metal base or an alkaline earth metal base.
The method of claim 1 , wherein the supernatant is neutralized with sodium hydroxide or sodium carbonate.
10. The method of claim 1, wherein the supernatant is neutralized with calcium hydroxide or calcium carbonate.
11. The method of claim 1 , wherein the water in step (d) is removed by
lyophilization or spray drying.
12. The method of claim 1, wherein the chicken sternum is heated in the presence of aqueous hydrochloric acid at a temperature of from 58 °C to 62 °C for 16 to 18 hours, wherein the ratio of chicken sternum per mole of acid is from 500 g chicken sternum/mole of acid to 1,000 g chicken sternum/mole of acid.
13. The method of claim 12, wherein the supernatant is neutralized with calcium hydroxide or calcium carbonate.
14. Hydrolyzed collagen produced by the method in any one of claims 1-12.
15. The hydrolyzed collagen of claim 14, wherein the hydrolyzed collagen has an average molecular weight of less than 10 kDa.
16. The hydrolyzed collagen of claim 14, wherein the hydrolyzed collagen
comprises one or more calcium salts in the amount of less than 25% by weight of the hydrolyzed collagen.
17. The hydrolyzed collagen of claim 14, wherein the hydrolyzed collagen
comprises hyaluronic acid in the amount of less than 2% by weight of the hydrolyzed collagen.
18. The hydrolyzed collagen of claim 14, wherein the hydrolyzed collagen
comprises chondroitin sulfate in the amount of less than 4% by weight of the hydrolyzed collagen.
EP17770897.1A 2016-03-22 2017-03-20 Hydrolyzed collagen compositions and methods of making thereof Active EP3432860B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662311575P 2016-03-22 2016-03-22
PCT/US2017/023181 WO2017165281A1 (en) 2016-03-22 2017-03-20 Hydrolyzed collagen compositions and methods of making thereof

Publications (3)

Publication Number Publication Date
EP3432860A1 true EP3432860A1 (en) 2019-01-30
EP3432860A4 EP3432860A4 (en) 2020-04-08
EP3432860B1 EP3432860B1 (en) 2022-12-21

Family

ID=59900669

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17770897.1A Active EP3432860B1 (en) 2016-03-22 2017-03-20 Hydrolyzed collagen compositions and methods of making thereof

Country Status (4)

Country Link
US (2) US10253090B2 (en)
EP (1) EP3432860B1 (en)
CA (1) CA3056759C (en)
WO (1) WO2017165281A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202606A1 (en) * 2018-11-06 2020-05-07 Gelita Ag Recombinant production of a collagen peptide preparation and its use

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907580A (en) 1972-11-12 1975-09-23 Astor Margaret Nail varnishes
US4032464A (en) 1976-01-14 1977-06-28 Helena Rubinstein, Inc. Creamy nail lacquer remover
US4130555A (en) 1977-09-06 1978-12-19 Nippi Incorporated Peptide mixtures derived from collagenous material or gelatin
US4344967A (en) 1979-08-07 1982-08-17 Devro, Inc. Film forming composition and uses thereof
US4485037A (en) 1983-08-02 1984-11-27 Chesebrough-Pond's Inc. Nail polish remover
LU85067A1 (en) 1983-10-28 1985-06-19 Oreal COMPOSITION AND METHOD FOR TREATING KERATINIC MATERIALS WITH AT LEAST ONE ANIONIC POLYMER AND AT LEAST ONE QUATERNIZED PROTEIN
LU86361A1 (en) 1986-03-19 1987-11-11 Oreal AQUEOUS COSMETIC COMPOSITION WITH DIFFERENT FOAM FOR THE TREATMENT OF HAIR AND SKIN
US4784986A (en) 1986-10-30 1988-11-15 Polydex Pharmaceuticals Ltd. Skin treatment compositions and method of use thereof
AU633430B2 (en) 1990-05-15 1993-01-28 Unilever Plc Nail polish remover composition
JP2879947B2 (en) 1990-06-04 1999-04-05 鐘紡株式会社 Hair modifier
US5306504A (en) 1992-12-09 1994-04-26 Paper Manufactures Company Skin adhesive hydrogel, its preparation and uses
DE4444238A1 (en) 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
US6337389B1 (en) 1995-03-17 2002-01-08 Bioscience Consultants, L.L.C. Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof
ATE205855T1 (en) 1995-12-16 2001-10-15 Planton Gmbh VERTEBRATE PROTEINS AND THEIR COSMETIC PREPARATIONS EFFECTIVE AGAINST BACTERIA, MYCOTA AND VIRUSES
ATE423568T1 (en) 1996-01-05 2009-03-15 Autoimmune Inc METHOD FOR PRODUCING TYPE-II COLLAGEN
US6090915A (en) 1996-10-18 2000-07-18 Hormel Foods Corporation Collagen or gelatin crumble composition and uses
US5814328A (en) * 1997-01-13 1998-09-29 Gunasekaran; Subramanian Preparation of collagen using papain and a reducing agent
JP3687277B2 (en) 1997-06-10 2005-08-24 サンスター株式会社 Whitening cosmetics
US6025327A (en) 1997-08-08 2000-02-15 Biocell Technology, Llc Hydrolyzed collagen type II and use thereof
FR2782607B1 (en) 1998-08-31 2000-11-24 Diana PROCESS FOR OBTAINING AVIAN BIOLOGICALS
US20030044456A1 (en) 1998-10-23 2003-03-06 Nippon Meat Packers, Inc. Hypoallergenic gelatin
DE19911056B9 (en) 1999-03-12 2005-09-08 Biotec Asa Cosmetic preparations and their use
FR2799758B1 (en) 1999-10-15 2002-05-17 Exsymol Sa COMPLEX BASED ON BIOLOGICALLY ASSIMILABLE ORTHOSILICIC ACID, IN SOLID, STABLE AND CONCENTRATED FORM, AND PREPARATION METHOD
US7250174B2 (en) 1999-12-07 2007-07-31 Schott Ag Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
WO2001095728A1 (en) 2000-06-13 2001-12-20 Fd Management, Inc. Cosmetic composition for stressed skin under extreme conditions
US6497889B2 (en) 2000-06-20 2002-12-24 Kyowa Hakko Kogyo Co., Ltd. Cosmetics
DE10035210A1 (en) 2000-07-20 2002-01-31 Beiersdorf Ag Shaped soap product containing talc, one or more fatty acids in the form of their alkali soaps and one or more cationic surfactants in the absence of alkyl (oligo) glycosides
US7083820B2 (en) 2000-09-29 2006-08-01 Schilling Marvin L Method for producing biologically active products
US6838440B2 (en) 2001-01-24 2005-01-04 Collagen Nutraceuticals, Inc. Kolla2-desiccated avian sternal cartilage powder
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
CN100577136C (en) 2002-06-19 2010-01-06 昭和电工株式会社 Hydrous gel and production process and use of the hydrous gel
EP1635782A1 (en) 2003-05-24 2006-03-22 JUVENA (International) AG Tissue culture media used as a component of cosmetics
CN1590408A (en) 2003-08-28 2005-03-09 南京宝生药业有限公司 Preparation technology of globe fish peptide and its medical health care use
EP1667640B1 (en) 2003-09-22 2009-08-05 JUVENA (International) AG Skin and hair care preparation containing rotein hydrolysats
US20090312524A1 (en) 2003-11-28 2009-12-17 Alternative Sourced Collagen, Llc Compositions and methods comprising collagen
ES2380940T3 (en) 2004-06-28 2012-05-21 Dsm Ip Assets B.V. Cosmetic compositions containing protein hydrolysates
TWI263678B (en) 2004-10-27 2006-10-11 Fisheries Res Inst Council Of Collagen of fish scale and method of making thereof
TW200640535A (en) 2005-02-07 2006-12-01 Showa Denko Kk Hair relaxer
KR100676285B1 (en) * 2005-03-11 2007-01-30 세원셀론텍(주) Manufactured product using and collagen solution manufacturing method and collagen separation method of animal tissue
US20110123579A1 (en) 2005-05-12 2011-05-26 Fatemeh Mohammadi Cosmetic Composition For Diminishing The Appearance Of Lines And Pores
US20060257346A1 (en) 2005-05-12 2006-11-16 Fatemeh Mohammadi Cosmetic composition for diminishing the appearance of lines and pores
WO2006121214A2 (en) 2005-05-12 2006-11-16 Showa Denko K.K. Permanent waving and simultaneously coloring agent
JP4722561B2 (en) 2005-05-27 2011-07-13 昭和電工株式会社 Permanent hair processing agent containing heterocyclic mercapto compound
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
US7405456B2 (en) 2005-09-14 2008-07-29 Sigurd Microelectronics Corp. Optical sensor chip package
JP4975751B2 (en) 2005-10-13 2012-07-11 グ、ジェニファー、エル. Minerals, collagens and chelates and their production and use
US7763594B2 (en) * 2005-11-30 2010-07-27 Bioiberica, S.A. Compositions for the treatment of osteoarthritis and to nourish the synovial fluid
ES2288791B1 (en) * 2006-02-10 2008-12-01 Masterfarm, S.L. PROCEDURE FOR OBTAINING A COLLAGEN HYDROLYZE. ENZYMATIC HYDROLYZE OF COLLAGEN OBTAINABLE BY THE PROCEDURE AND USES OF THE SAME.
FR2900155B1 (en) 2006-04-21 2008-06-27 Diana Naturals Sa AVIAN CARTILAGE HYDROLISATE, PROCESS FOR OBTAINING AND USES
KR101435228B1 (en) 2006-07-14 2014-08-28 디에스엠 아이피 어셋츠 비.브이. Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders
JP5170577B2 (en) 2006-07-14 2013-03-27 ディーエスエム アイピー アセッツ ビー.ブイ. Composition comprising rosehips and other active agents for the treatment of inflammatory disorders
JP5180556B2 (en) 2006-10-13 2013-04-10 昭和電工株式会社 Skin external preparations and cosmetics containing ubiquinone derivatives or salts thereof, and methods of use thereof
WO2008059927A1 (en) 2006-11-15 2008-05-22 Meiji Seika Kaisha, Ltd. Collagen peptide composition and food or beverage containing the same
US7758820B2 (en) 2006-12-21 2010-07-20 Uop Llc Apparatus and process for regenerator mixing
US20080206172A1 (en) 2007-02-27 2008-08-28 Fatemeh Mohammadi Clear sunscreen gels and methods of use thereof
US8414872B2 (en) 2007-09-10 2013-04-09 Liquid Keratin, Inc. Hair straightening formulations, methods and systems
JP2009091298A (en) 2007-10-10 2009-04-30 Asuka Corporation:Kk Skin-revitalizing cosmetic
CN101215314A (en) * 2007-12-27 2008-07-09 黄晓东 Process for preparing II type soft bone collagen
US20100273877A1 (en) 2007-12-28 2010-10-28 Showa Denko K.K. Emulsified skin external preparations and cosmetics
US20100322887A1 (en) 2008-02-06 2010-12-23 Showa Denko K.K. Hair nourishing cosmetic
JP5451975B2 (en) 2008-02-13 2014-03-26 株式会社ロッテ Method for deodorizing collagen peptides
WO2009127256A1 (en) 2008-04-17 2009-10-22 Jisbrey, S.A Hydronium stabilized and dissoluble silicic acid nanoparticles: preparation, stabilization and use
DE102008036576A1 (en) 2008-07-31 2010-02-04 Gelita Ag Particles of collagen material and method of manufacture
JP5715962B2 (en) 2009-01-30 2015-05-13 バイヤースドルフ・アクチエンゲゼルシヤフトBeiersdorf Aktiengesellschaft Cosmetic or dermatological preparation comprising collagen, chitosan, glycosylaminoglycan and cell growth-promoting peptide and / or cell complex
US8748499B2 (en) 2009-04-10 2014-06-10 Interhealth Nutraceuticals, Inc. Collagen dispersion and method of producing same
ES2566551T3 (en) 2009-07-16 2016-04-13 Sunstar Inc. Material containing proteoglycan
DE102009028052A1 (en) 2009-07-28 2011-02-03 Henkel Ag & Co. Kgaa Cosmetic cleanser with new active ingredient mixture
FR2949044B1 (en) 2009-08-12 2021-05-07 Expanscience Lab COMPOSITION INCLUDING A FRACTION OF THE UNSAPONIFIABLE
DE102009054665A1 (en) 2009-12-15 2011-06-16 Henkel Ag & Co. Kgaa Non-weighty hair treatment products
JP2011136945A (en) 2009-12-28 2011-07-14 Lotte Co Ltd Sebum secretion suppressing agent and food, drink and composition produced by using the same
JP6086727B2 (en) 2010-06-15 2017-03-01 国立大学法人 奈良先端科学技術大学院大学 Retinol-modified collagen, method for producing the same, and external composition for skin containing the same
JP5753356B2 (en) * 2010-09-13 2015-07-22 株式会社龍泉堂 Method for extracting non-denatured type II collagen having an active epitope
JP2012097049A (en) 2010-11-04 2012-05-24 Hydrox Kk External use composition for skin
KR101346661B1 (en) 2010-11-15 2014-02-06 부경대학교 산학협력단 Cosmetic composition for preventing skin aging comprising chitooligosaccharides
DE102010060564A1 (en) 2010-11-15 2012-05-16 Gelita Ag Use of collagen hydrolyzate to improve the health of human skin, hair and / or nails
DE102010063578A1 (en) 2010-12-20 2012-06-21 Henkel Ag & Co. Kgaa Cosmetic cleanser
US20130310540A1 (en) 2011-01-19 2013-11-21 Sunstar Inc. Extract of aquatic animal cartilage
DE102011015191A1 (en) 2011-03-25 2012-09-27 Henkel Ag & Co. Kgaa Process for the preparation of a conditioned cleaning agent
US9347081B2 (en) 2011-04-19 2016-05-24 Bioiberica, S.A. Cartilage product
US8344106B1 (en) 2011-08-03 2013-01-01 Robert den Hoed Collagen mixture and method of making the same
US8652530B1 (en) 2013-01-23 2014-02-18 Cartilast Corp. Preservation of the biological activity of undenatured type II collagen
CA3099905A1 (en) * 2017-05-11 2018-11-15 Avicenna Nutracetical, Llc Methods for producing collagen

Also Published As

Publication number Publication date
CA3056759C (en) 2024-01-23
CA3056759A1 (en) 2017-09-28
US20190211078A1 (en) 2019-07-11
US10253090B2 (en) 2019-04-09
US20180319866A1 (en) 2018-11-08
EP3432860B1 (en) 2022-12-21
US11028147B2 (en) 2021-06-08
WO2017165281A1 (en) 2017-09-28
EP3432860A4 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
AU2020200381B2 (en) Chitin, hydrolysate and method for the production of one or more desired products from insects by means of enzymatic hydrolysis
Shanmugam et al. Antioxidative peptide derived from enzymatic digestion of buffalo casein
KR101071338B1 (en) Method of Producing Collagen Peptide from Marine Organism and Collagen Peptide Produced by the Method
US11702447B2 (en) Methods for producing collagen
CN112778412B (en) Preparation method of low-endotoxin collagen
CN112813127B (en) Method for preparing collagen peptide from chondroitin sulfate ultrafiltration waste liquid
JP4226299B2 (en) Method for producing fish-derived gelatin peptide
Song et al. Extraction optimization and characterization of collagen from the lung of soft-shelled turtle Pelodiscus sinensis
KR100679712B1 (en) Process for preparing collagen from starfish
US11028147B2 (en) Hydrolyzed collagen compositions and methods of making thereof
RU2567171C1 (en) Method for production of acetic dispersion of high molecular fish collagen
El Amine Effect of gelatin drying methods on its amphiphilicity
KR20040108147A (en) producing method of protein hydrolysates from fish scale
Hernández-Ruiz et al. Collagen peptide fractions from tilapia (Oreochromis aureus Steindachner, 1864) scales: Chemical characterization and biological activity
Vázquez et al. Tailor-made process to recover high added value compounds from fishery by-products
CN105255981B (en) A kind of preparation method of non denatured jellyfish collagen
Jain et al. Bioprocessing of Chicken Meat and Egg Processing Industries' Waste to Value‐Added Proteins and Peptides
Sakunde et al. Effect of rendering temperature on collagen content from the poultry skin
Toma et al. Methods for obtaining collagen from various fish sources.
Preda et al. Cytotoxicity evaluation and physicochemical properties of collagen isolated from silver carp tails as potential biomaterial
Hasdar et al. Comparative Quality of Proteins and Morphological Structures of Gelatin From Sheepskin With Acid and Alkaline Treatment
Matouri Pressurized Hot Water Hydrolysis of Shrimp Shell and Chicken Feet for Value-added Compounds Production
Esmaeili Kharyeki Evaluation of the physicochemical and functional properties and, microstructure of protein isolates from grass carp (Ctenopharyngodon idella)
US20190194297A1 (en) Process to extract and recover keratin and keratin associated protein from animal body parts
Riaz et al. Gelatin in Halal Food Production

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101AFI20200303BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220704

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017064820

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1538625

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230321

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230323

Year of fee payment: 7

Ref country code: FR

Payment date: 20230322

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1538625

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230322

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230323

Year of fee payment: 7

Ref country code: DE

Payment date: 20230329

Year of fee payment: 7

Ref country code: BE

Payment date: 20230323

Year of fee payment: 7

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230323

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230421

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230401

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230421

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017064820

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

26N No opposition filed

Effective date: 20230922

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240318

Year of fee payment: 8

Ref country code: NL

Payment date: 20240318

Year of fee payment: 8